CIMT 2014 – Call for Abstracts

Mainz, February 05, 2014 – The Association for Cancer Immunotherapy (CIMT) is calling for abstract submissions by February 28. All accepted abstracts will be presented as posters during the CIMT Annual Meeting that takes place May 6-8 in Mainz, Germany. From all accepted entries, selected abstracts will be presented as short talks at the meeting, which is Europe’s largest conference focused on cancer immunotherapy research and development. For abstract submission and conference information, go to

Based in Mainz, Germany, CIMT collaborates with major international cancer research organizations including TRON and is a partner of the regional Cluster for Individualized ImmuneIntervention (Ci3).

The 2014 CIMT Annual Meeting will address the integration of science and game-changing new technologies, personalized medicines that are on the verge to enter clinical testing, promising cell therapies, tumor micro-milieu studies that will determine therapeutic options, and synergistic combination therapies.

The program committee expects key discussions on highly potent instruments that expedite the development of novel cancer diagnostics and therapies.

CIMT 2014 will include a special session on immunoinformatics and genomics. The session will address data analysis and interpretation, tumor genomics using next generation sequencing, immunogenicity predictions and integrated use in clinical cancer immunotherapy.

In addition, CIP (CIMT Immunoguiding Program) and CIMT-RRG (Regulatory Research Group) will hold sessions and panel discussions that focus on standardized and innovative tools for improving the quality of immunomonitoring, and the regulatory setting for the translation of scientific knowledge to drug development. The RRG session will specifically address preclinical study design suited for a new class of immunotherapies.

2014 scientific sessions are Tumor Vaccination, Combination Therapy, Improving Immunity, Immunoguiding, Immunoinformatics and Genomics, Cellular Therapy, Regulatory Research and Tumor Microenvironment.
For more information, go to